drugset / Trial / NCT01929096

Compound Edaravone Injection for Acute Ischemic Stroke

NCT01929096

Phase 2 Completed 400 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

1. To investigate the efficacy and safety of multi-doses Compound Edaravone Injection versus Edaravone Injection for acute ischemic stroke patients; 2. To provide evidence for the design of Compound Edaravone Injection Phase III trial.

Timeline

Start
2013-08
Primary completion
2014-12
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Edaravone Unknown 30 mg Intravenous
Subject Edaravone Dexborneol Unknown 12.5 mg Intravenous
Subject Edaravone Dexborneol Unknown 37.5 mg Intravenous
Subject Edaravone Dexborneol Unknown 62.5 mg Intravenous

Indications